e8vk
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 28, 2008
Artes Medical, Inc.
(Exact Name of Registrant as Specified in Charter)
         
Delaware   001-33205   33-0870808
(State or Other Jurisdiction of Incorporation)   (Commission File
Number)
  (I.R.S. Employer
Identification No.)
5870 Pacific Center Boulevard
San Diego, California 92121

(Address of Principal Executive Offices, with zip code)
(858) 550-9999
(Registrant’s telephone number, including area code)
n/a
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 


TABLE OF CONTENTS

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
SIGNATURE


Table of Contents

Item 5.02.   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
     On February 28, 2008, the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Artes Medical, Inc. (the “Company”) met and fixed the base salaries and target bonus amounts for the Company’s executive officers for fiscal year 2008. The base salaries and the target bonus amounts for the Company’s principal executive officer, principal financial officer and named executive officers are as follows:
                 
Name and Title   Base Salary   Target Bonus Amount
Christopher J. Reinhard, Executive Chairman of the Board
  $ 150,000     $ 75,000  
Diane S. Goostree, President and Chief Executive Officer
    325,000       162,500  
Peter C. Wulff, Executive Vice President and Chief Financial Officer
    250,000       87,500  
Larry J. Braga, Vice President - Manufacturing
    225,000       67,500  
     In accordance with the Company’s Annual Bonus Incentive Plan, 50% of the target bonus amounts for these executive officers will be based on the Company’s achievement of corporate goals during fiscal year 2008 and the remaining 50% will be based on the individual performance of the executive officer during the year.
     The Board also granted stock options to the executive officers on February 28, 2008 under the Company’s 2006 Equity Incentive Plan (the “Plan”). The stock grants for the Company’s principal executive officer, principal financial officer and named executive officers are as follows:
         
    Number of
Name and Title   Shares
Christopher J. Reinhard, Executive Chairman of the Board
     
Diane S. Goostree, President and Chief Executive Officer
    93,024  
Peter C. Wulff, Executive Vice President and Chief Financial Officer
    26,391  
Larry J. Braga, Vice President — Manufacturing
    40,683  
     The stock options have an exercise price of $2.20 per share, the closing sale price of the Company’s common stock as reported on the Nasdaq Global Market on the grant date. The stock options vest over four years, with 25% of the option shares vesting 12 months after the grant date, and the remaining 75% of the option shares vesting in 36 equal monthly installments thereafter. The stock options will

 


Table of Contents

automatically terminate on February 27, 2009, without any vesting, if the Company fails to satisfy a revenue milestone set by the Committee for fiscal year 2008. The stock options may be accelerated in the event of certain corporate transactions as provided in the Plan.

 


Table of Contents

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Dated: March 5, 2008
         
  ARTES MEDICAL, INC.
 
 
  By:   /s/ Karla R. Kelly    
    Karla R. Kelly
Chief Legal Officer, General Counsel and 
 
    Corporate Secretary